Delivery Order SPE2DR25D3016-SPE2DR26FG3LE
- Not listed
- The Defense Logistics Agency awarded a $49,795.38 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors on January 13, 2026, with an ultimate completion date of January 14, 2026. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The pharmaceutical product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. AmerisourceBergen is a subsidiary of parent company Cencora, Inc., a major...
- The Defense Logistics Agency awarded a delivery order valued at $2,520.37 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of June 3, 2025. This is a firm fixed price, non-set-aside contract supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for military and veteran healthcare systems through the DLA's...
- The Defense Logistics Agency awarded a $41,759.43 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 10, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is the vendor's...
- The Defense Logistics Agency awarded a delivery order valued at $2,859.55 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of April 23, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical vendor that...
- The Defense Logistics Agency awarded a delivery order valued at $55,027.37 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 21, 2025. This firm fixed-price contract, awarded on August 20, 2025, represents a non-competitive set-aside delivery against AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,149.50 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as a hub for the company's extensive pharmaceutical...
- The Defense Logistics Agency awarded a $14,120.29 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of December 23, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor and healthcare solutions provider for federal medical procurement, particularly supporting military...
- The Defense Logistics Agency awarded a delivery order valued at $36,135.13 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with a completion date of December 23, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single pharmaceutical delivery under AmerisourceBergen's broader supply relationship with the federal government. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a $77,269.39 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of October 16, 2025. This non-set-aside, firm fixed-price contract represents a child order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was made competitively and reflects...
- The Defense Logistics Agency awarded a $18,521.79 firm fixed-price delivery order to AmerisourceBergen Drug Corp (Conshohocken, PA) on January 13, 2026, for the supply of REPATHA 140 mg/ml SureClick auto-injectors, with completion scheduled for January 14, 2026. This non-competitive delivery order represents a routine pharmaceutical procurement supporting federal medical supply requirements. The award is issued under AmerisourceBergen's parent company Cencora, Inc.'s substantial Indefinite...
- SPE2DR25D3016Indefinite Delivery Contract
- SPE2DR25D3016-SPE2DR26FG3LEDelivery Order
The Defense Logistics Agency awarded a $2,436.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 MG/ML SureClick auto-injectors on January 15, 2026, with completion scheduled for January 16, 2026. This non-set-aside award is being fulfilled at the vendor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and subsidiary of Cencora, Inc., serves as a critical supplier to federal medical procurement, particularly for military and veteran healthcare systems. This delivery order operates under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle, enabling the company to supply an extensive range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs worldwide. REPATHA, an PCSK9 inhibitor used for cholesterol management, represents one of the specialized pharmaceutical products available through this contract vehicle, which supports the Defense Health Agency, U.S. Coast Guard, and other federal government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 1/14/26 |